18. LICENSE AND EXCLUSIVITY COMPENSATION. 

 

18.1 Payments; Extension of Exclusivity Period.

(a) Upfront License Fee and Prepayment. Hospira shall within [*] after the Effective Date (and in any event, before December 30, 2011) pay to CyDex a non-refundable upfront license fee of $500,000, in consideration of the rights granted Hospira under this Agreement. In addition, Hospira shall within [*] after the Effective Date (and in any event, before December 30, 2011) pay to CyDex $2,500,000 by wire transfer as a one-time materials purchase prepayment usable only as a cumulative $2,500,000 credit toward future purchases of Captisol hereunder. Such credit shall be applied to the first $2,500,000 of Captisol purchased hereunder, until exhausted. In the event that this Agreement is terminated, then to the extent so provided in Section 11.4 CyDex shall immediately make a payment to Hospira in the amount of any such remaining prepayment credit.

 

(b) Extension of Exclusivity Period. To retain the benefits of having the Exclusivity Period remain in force for additional time, Hospira shall have the option to extend one or more times the expiration date of the Exclusivity Period. Not more than [*] before and not less than [*] before the Exclusivity Period would otherwise expire (taking into account any previous proper extension or extensions of the Exclusivity Period pursuant to this Section 4.1(b)), CyDex shall deliver to Hospira written notice that the Exclusivity Period is set to expire. Hospira may, in its sole discretion, extend the Exclusivity Period by making a non-refundable payment, by wire transfer, of $[*] to CyDex within [*] after the receipt of CyDex’s notice. Each such extension shall extend the erstwhile expiration date of the Exclusivity Period for [*] beyond when it would otherwise have expired. For avoidance of doubt: (i) such option to extend can be exercised in compliance with this Section 4.1(b) multiple times, but no extension can extend the Exclusivity Period beyond the end of the Term, (ii) if CyDex does not provide notice to Hospira at least [*] before the end of the then current term of the Exclusivity Period, the Exclusivity Period will automatically extend for [*] after Hospira’s receipt of any such notice and Hospira shall have the right to further extend the Exclusivity Period as set forth above by making the required payment within [*] after receipt of CyDex’s notice, and (iii) the Exclusivity Period cannot be resuscitated after it has expired or terminated.

 

18.3 Taxes. All amounts due hereunder exclude all applicable sales, use, and other taxes and duties, and Hospira will be responsible for payment of all such taxes (other than taxes based on CyDex’s income), arising from the payment of amounts due under this Agreement. The parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of payments made by Hospira to CyDex under this Agreement. To the extent Hospira is required to deduct and withhold taxes on any payment to CyDex, Hospira shall pay the amounts of such taxes to the proper governmental authority in a timely manner and promptly transmit to CyDex official receipts issued by the appropriate taxing authority and/or an official tax certificate, or such other evidence as CyDex may reasonably request, to establish that such taxes have been paid. CyDex shall provide Hospira any tax forms that may be reasonably necessary in order for Hospira to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. CyDex shall use reasonable efforts to provide any such tax forms to Hospira at least [***] before the due date for any payment for which CyDex desires that Hospira apply a reduced withholding rate. Each party shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable law, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the party bearing such withholding tax or value added tax.

 

19. RECORDS; AUDIT. 

 

19.1 Records and Reports.

(a) Records. During the Term and for a period of [*], Hospira shall, and shall require its Affiliates to, maintain accurate records relating to Net Sales of the Finished Product.

 

(b) Reports. During the Term, Hospira shall provide CyDex with written a report that identifies whether each respective Section 4.1(c) milestone has been achieved.

 

19.2 Audit. Upon reasonable prior notice, such Section 5.1 records shall be available during regular business hours for examination and audit at the expense of CyDex by an independent certified public accountant selected by CyDex and reasonably acceptable to Hospira, for the sole purpose of verifying Net Sales. CyDex shall [*]. Such records may not be audited more often than [*] and the records for any period may not be audited more than once. During any audit, the scope of such audit shall only include, with respect to those items of deduction for which Hospira, under its then-current system, calculates using a fixed allocation system, a review of actual allocated deductions thereunder unless and until such time as Hospira has changed its system to reflect actual deductions for such category of deductions. In the event that Hospira begins tracking actual costs and deductions on a product by product basis generally (which it has no obligation to do hereunder), Hospira will implement such actual tracking for purposes of this Agreement in lieu of fixed allocation percentages and the calculation of such actual costs and deductions shall thereafter become subject to audit pursuant to this Section 5.2. All information learned in the course of any audit or inspection under this Section 5.2 shall be deemed to be Confidential Information of Hospira, subject to the terms and provisions of Section 7 below.

 

KASAN_기술이전, License, 생산위수탁 계약서에서 Royalty Payment 관련 영문계약 조항 샘플 –

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.16 13:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

8. PAYMENT.

8.1 Initial Fee. In consideration of the license and sublicense granted by Licensor to Licensee in accordance with Sections 2.1 and 2.2, respectively, and the assignments by Licensor to Licensee in accordance with Section 2.3, Licensee shall pay to Licensor a one-time, nonrefundable, non-creditable initial fee of Fifty Million Dollars ($50,000,000) on the Effective Date. 

 

8.2 Milestone Payments. 

(a) Launch Milestone Payment. Licensee shall notify Licensor promptly of the date of the Noctiva Launch, but in no event later than twenty (20) days thereafter. In further consideration of the license and sublicense granted by Licensor to Licensee in accordance with Sections 2.1 and 2.2, respectively, and the assignments by Licensor to Licensee in accordance with Section 2.3, Licensee shall pay to Licensor a one-time, nonrefundable, non-creditable payment of Twenty Million Dollars ($20,000,000) in respect of such Noctiva Launch on the earlier to occur of: (i) the thirtieth (30th) day immediately following the date of the Noctiva Launch and (ii) June 30, 2018. Such payment shall not require Licensor to provide any invoice in respect thereof.

 

Tier One Commercialization Milestone Payments. Licensee shall notify Licensor promptly, but in no event later than thirty (30) days, after the first achievement of the relevant sales milestone for the Product as set forth in the table below in this Section 8.2(b). In further consideration of the license and sublicense granted by Licensor to Licensee in accordance with Sections 2.1 and 2.2, respectively, and the assignments by Licensor to Licensee in accordance with Section 2.3, Licensee shall make the following one-time, nonrefundable, non-creditable milestone payments to Licensor within thirty (30) days after receipt of an invoice from Licensor therefor.

 

(i) Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications in the aggregate reach $50 million on a cumulative basis beginning with the first dollar of Royalty-Bearing Net Sales

 

(ii) Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications in the aggregate reach $[*] on a cumulative basis beginning with the first dollar of Royalty-Bearing Net Sales

 

(iv) Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications in the aggregate reach $200 million on a cumulative basis beginning with the first dollar of Royalty-Bearing Net Sales

 

(b) Tier Two Commercialization Milestone Payments. Licensee shall notify Licensor promptly, but in no event later than thirty (30) days, after the first achievement of the relevant sales milestone for the Product as set forth in the table below in this Section 8.2(c). In further consideration of the license and sublicense granted by Licensor to Licensee in accordance with Sections 2.1 and 2.2, respectively, [and the assignments by Licensor to Licensee in accordance with Section 2.3,] Licensee shall make the following one-time, nonrefundable, non-creditable milestone payments to Licensor within thirty (30) days after receipt of an invoice from Licensor therefor; provided, however, in the event that the last of the milestone payments described in the table below becomes payable, the due date for Licensee to make payment to Licensor of such milestone payment will be the first anniversary of the payment of the $[*] milestone payment in the penultimate row of the table below. 

 

(i) Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications reach $300 million in any consecutive 12-month period beginning after achievement of milestone (iv) described in Section 8.2(b)

 

(ii) Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications reach $ 1.5 billion in any consecutive 12-month period beginning after achievement of milestone (iv) described in Section 8.2(b)

 

(c) Change of Control Payment. If a Change of Control occurs, simultaneously with the consummation of such Change of Control, Licensee shall pay to Licensor the amount of [*] Dollars ($[*]) less the sum of the following allocable portions of any of the milestone payments described in Section 8.2(b) that are paid to Licensor prior to such Change of Control: 

 

8.3 Royalties; Non-Royalty Commercialization Consideration. 

(a) Royalties. In further consideration of the license and sublicense granted by Licensor to Licensee in accordance with Sections 2.1 and 2.2, respectively, Licensee shall pay Licensor royalties on Net Sales of the Product by Licensee and any of its Sublicensees and Third Party Distributors in accordance with the rates set forth in the tables set forth below in this Section 8.3(a)(i).

 

(b) Third Party Royalties. 

(i) CPEX and Reprise. Licensor will be responsible for payment of any amounts payable to CPEX and Reprise under the terms of the CPEX License Agreement and the Reprise License Agreement, respectively. 

 

(ii) Other Third Parties.

(A) In the event that after the Effective Date Licensee reasonably determines that it is necessary or advisable for Licensee to obtain a license under any Patent Rights from any Third Party in order for Licensee (each a “Third Party License”; collectively, “Third Party Licenses”), its Sublicensees, and any Third Party Distributors to Commercialize the Product in the Field in any country in the Territory as contemplated by this Agreement, the Parties shall discuss the best course of action to resolve such potential license requirement, provided that such discussions shall not limit or delay Licensee’s right to obtain any such Third Party Licenses.

 

(B) With respect to any such Third Party Licenses that Licensor reasonably agrees are necessary for Licensee to be able to Commercialize the Product in the Field in any country in the Territory, Licensee shall have the right to set off an amount equal to [*] percent ([*]%) of the aggregate of any and all payments required to be paid by Licensee to the licensors under such Third Party Licenses in respect of any Calendar Quarter against payments otherwise payable to Licensor under Section 8.3(a) in respect of such Calendar Quarter; provided, however, that in no event shall the aggregate set off in any Calendar Quarter resulting from such payments in respect of such Third Party Licenses exceed an amount equal to [*] percent ([*]%) of the royalty payments otherwise payable to Licensor under Section 8.3(a) in respect of such Calendar Quarter.

 

(c) Royalty Term. Licensee’s obligation under Sections 8.3(a) to pay Licensor royalties on Net Sales of the Product in each country in Territory will apply to any and all sales or other dispositions of such the Product in such country made during the Term of this Agreement. 

 

(d) Generic Product. If, during the Royalty Term, one or more Third Parties is selling in any country in the Territory any product that is a Generic Product in relation to the Product being sold in such country by Licensee or any of its Sublicensees or Third Party Distributors, Licensee’s royalty obligations under Section 8.3(a) for sales in such country of the Product shall be reduced as follows: 

 

If the Generic TRxs-to-Total TRxs Percentage in such country during such Calendar Quarter is: Licensee’s royalty obligations under Section 8.3(a) shall be reduced by the Percentage Indicated Below

 

8.4 Reports and Payments. During the Term of this Agreement following the First Commercial Sale of the Product by Licensee, its Sublicensees, or its Third Party Distributors, within five (5) Business Days after the filing by Licensee of each Form 10-K or Form 10-Q, Licensee shall pay to Licensor the royalty payments payable by Licensee for the Calendar Quarter preceding the Calendar Quarter in which such Form 10-K or 10-Q, as applicable, is filed, and shall provide a report showing, on a country-by-country basis: 

 

(a) the net quantity of the Product sold, total gross sales, an itemized list of the deductions applied to total gross sales, and Net Sales of the Product sold in the Calendar Quarter in respect of which such report has been prepared; 

 

(b) the calculation in Dollars of royalty payments due hereunder with respect to such Net Sales, including any deductions for any offsets in accordance with Section 8.3(b)(ii);

 

(c) withholding taxes on Net Sales, if any, required by Applicable Laws to be deducted with respect to such royalties; and

 

(d) the rate of exchange used by Licensee in determining the amount of Dollars payable hereunder.

 

 

If no royalty or other payment is due for any period hereunder, Licensee shall so report.

 

Currency of Payment. All payments to be made under this Agreement shall be made in Dollars by electronic funds transfer to such bank accounts as Licensor may designate from time to time. When Licensee or any of its Sublicensee of Third Party Distributors sells the Product for monies other than Dollars, Licensee will convert any non-Dollar currencies into Dollars with the exchange rate for the purchase of Dollars with such domestic currency as quoted by The Wall Street Journal, New York edition, at an average rate for the Calendar Quarter for which the payment is made.

 

8.5 Accounting. 

(a) Licensee shall determine Net Sales with respect to the Product sold using its standard accounting procedures, consistent with GAAP, as if the Product was a solely owned product of Licensee, except as specifically provided in this Agreement. In the case of amounts to be determined by Third Parties (for example, Net Sales by Sublicensees), such amounts shall be determined in accordance with generally accepted accounting principles in effect in the country in which such Third Party is engaged. Licensor and Licensee also recognize that such procedures may change from time to time and that any such changes may affect the definition of Net Sales. Licensor and Licensee agree that, where such changes are economically material to Licensor, adjustments shall be made to compensate Licensor in order to preserve the same economics as are reflected under this Agreement under Licensee’s accounting procedures in effect prior to such change. Where the change is or would be material to Licensor, Licensee shall provide an explanation of the proposed change and an accounting of the effect of the change on the relevant revenue, cost, or expense category.

 

(b) In the event of the payment or receipt of noncash consideration in connection with the performance of activities under this Agreement Licensee shall advise Licensor of such transaction, including without limitation Licensee’s assessment of the fair market value of such noncash consideration and the basis therefor. Such transaction shall be accounted for on a cash equivalent basis, as mutually agreed by Licensor and Licensee in good faith.

 

(c) Withholding Tax. Notwithstanding anything to the contrary herein, in the event that withholding taxes apply with respect to any amounts due from Licensee hereunder, Licensee shall be entitled to withhold from any payment due to Licensor under this Agreement any taxes that Licensee is required to pay and such withholding shall decrease by an equivalent amount the payment due to Licensor. Licensee shall provide Licensor with notification of any anticipated withholding requirements with as much advance notice as practicable and shall cooperate in good faith with Licensor to legally minimize such withholding taxes. Licensee will timely pay to the proper governmental authority the amount of any taxes withheld and will provide Licensor with an official tax certificate or other evidence of tax obligation, together with proof of payment from the relevant governmental authority sufficient to enable Licensor to claim such payment of taxes. 

 

8.6 Books and Records; Audit Request. 

(a) During the term of this Agreement and for three (3) years thereafter, Licensee shall keep and maintain, and shall cause each of its Affiliates, and Sublicensees, if any, to keep and maintain, at their respective regular places of business complete and accurate books, records, and accounts in accordance with GAAP, or other accounting standards mandated by the U.S. Securities and Exchange Commission if applicable to Licensee, in sufficient detail to reflect all amounts required to be paid under this Agreement, as well as any other books, records or accounts required to be maintained in connection with the Product under any Applicable Laws, necessary to permit the audits contemplated under Section 8.8(b). Prior to destroying any books, records or accounts which are material to the Parties’ rights and obligations under this Agreement, Licensee must seek prior written consent from Licensor, which consent may not be unreasonably withheld.

 

 (b) During the term of this Agreement and for three (3) years thereafter, Licensor shall have access to and the right to examine such relevant records and accounts that Licensee is required to maintain pursuant to Section 8.8(a) at Licensee’s premises for the sole purpose of verifying the accuracy of any report or payment made under this Agreement in the three (3) preceding years; provided, however, that any such examination: (i) shall not occur more than once during each Calendar Year (except that if as a result of any audit pursuant to this Section 8.8(b), an error in favor of Licensee exceeding five percent (5%) of any payments previously reported as owed by Licensee to Licensor is discovered, the frequency of audits under this Section 8.10(b) shall not be so limited); (ii) shall be during normal business hours upon reasonable prior written notice which shall in no event be less than thirty (30) days; and (iii) shall not unreasonably interfere with Licensee’s operations and activities. If Licensor desires to audit such records, it shall engage an independent, certified public accountant reasonably acceptable to Licensee, to examine such records under conditions of confidentiality with respect thereto at least as stringent as those specified in Article 13. The expense of any such audit shall be borne by Licensor; provided, however, that, if an error of more than five percent (5%) in favor of Licensor is discovered as a result of such audit, then such expenses shall be paid by Licensee. If such accountant concludes that additional payment amounts were owed to Licensor during any period, Licensee shall pay such payment amount (including without limitation interest thereon from the date such amounts were payable) within thirty (30) days after the date Licensor delivers to Licensee such accountant’s written report so concluding, unless Licensee notifies Licensor of any dispute regarding the audit. If such accountant concludes that Licensee has overpaid any amounts to Licensor during any period, in Licensor’s discretion, Licensee may credit such amounts against future payments due Licensor or Licensor may pay such amounts (including without limitation interest thereon from the date such amounts were payable), unless Licensor notifies Licensee of any dispute regarding the audit. Any Information received by Licensor pursuant to this Section 8.10 shall be deemed to be Confidential Information of Licensee for purposes of Article 13. 

 

8.7 Blocked Currency. If by Applicable Laws or fiscal policy of a particular country, conversion into Dollars or transfer of funds of a convertible currency to the United States is restricted or forbidden, royalties accrued in such country shall be paid to Licensor in the country in local currency by deposit in a local bank designated by Licensor for such deposit, unless Licensor and Licensee otherwise agree. 

 

8.8 Interest. If Licensor does not receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due to Licensor from the due date until the date of payment at a rate equal to three month Dollar LIBOR Rate, as reported in the online edition of The Wall Street Journal as of Noon (New York Time) on such due date, or the maximum rate allowable by Applicable Laws, whichever is less. 

 

8.9 Transaction Expenses. Licensee shall upon execution and delivery of this Agreement pay the documented reasonable fees and expenses of Licensor’s advisors and counsel incurred by Licensor in structuring, negotiating, memorializing, and otherwise undertaking the transaction contemplated by this Agreement. Notwithstanding the foregoing, Licensee’s obligation under this Section 8.11 shall be limited to an amount not to exceed $2,000,000.

 

KASAN_제약회사 기술이전, License, 제조판매 계약서에서 Royalty Payment 관련 영문계약 조항

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.16 12:00
Trackback 0 : Comment 0

댓글을 달아 주세요


                                    

                                         

 

1.    사실관계 및 쟁점

 

경쟁업체 A를 퇴직한 후 경쟁사 B에 입사한 전직 연구원 CB사에서 경쟁업체 A사의 소스코드 등 영업비밀을 이용하여 새로운 프로그램 제품을 만들었습니다. 그 과정에 B사에서 C의 행위에 공모ㆍ가담한 사실이 인정되었고, 전직한 연구원 C뿐만 아니라 B사에 대해서도 부정경쟁방지 및 영입비밀보호에 관한 법률 위반(영업비밀누설등)죄가 인정되었습니다.

 

한편, 업무상배임 측면에서 연구원 C의 행위를 업무상배임의 불가벌적 사후행위에 해당하나 이에 공모ㆍ가담한 B 사의 행위에 대하여는 업무상배임의 공범이 성립된다고 판단한 원심판결이 형사법리상 문제가 있다고 다투어진 사안입니다.

 

대법원은 원심판결과 달리 다른 특별한 사정이 없는 한 이미 퇴사한 연구원 C는 더 이상 경쟁업체에 대하여타인의 사무를 처리하는 자의 지위에 있지 않아 업무상배임죄의 주체가 될 수 없으므로, 경쟁업체 B사도 업무상배임죄의 공범이 될 수 없다고 판결하였습니다.

 

2.    배임죄 법리 및 대법원 판결요지

 

업무상배임죄의 주체는 타인의 사무를 처리하는 지위에 있어야 한다. 따라서 회사직원이 재직 중에 영업비밀 또는 영업상 주요한 자산을 경쟁업체에 유출하거나 스스로의 이익을 위하여 이용할 목적으로 무단으로 반출하였다면 타인의 사무를 처리하는 자로서 그 업무상의 임무에 위배하여 유출 또는 반출한 것이어서 유출 또는 반출시에 업무상배임죄의 기수가 된다.

 

또한 회사직원이 영업비밀 등을 적법하게 반출하여 그 반출행위가 업무상배임죄에 해당하지 않는 경우라도, 퇴사시에 그 영업비밀 등을 회사에 반환하거나 폐기할 의무가 있음에도 경쟁업체에 유출하거나 스스로의 이익을 위하여 이용할 목적으로 이를 반환하거나 폐기하지 아니하였다면, 이러한 행위 역시 퇴사시업무상배임죄의 기수가 된다(대법원 2008. 4. 24. 선고 20069089 판결 등 참조).

그러나 회사직원이 퇴사한 후에는 특별한 사정이 없는 한 그 퇴사한 회사직원은 더 이상 업무상배임죄에서 타인의 사무를 처리하는 자의 지위에 있다고 볼 수 없고, 위와 같이 반환하거나 폐기하지 아니한 영업비밀 등을 경쟁업체에 유출하거나 스스로의 이익을 위하여 이용하더라도 이는 이미 성립한 업무상배임 행위의 실행행위에 지나지 아니하므로, 그 유출 내지 이용행위가 부정경쟁방지 및 영입비밀보호에 관한 법률 위반(영업비밀누설등)죄에 해당하는지 여부는 별론으로 하더라도, 따로 업무상배임죄를 구성할 여지는 없다고 보아야 한다.

 

그리고 위와 같이 퇴사한 회사직원에 대하여 타인의 사무를 처리하는 자의 지위를 인정할 수 없는 이상 제3자가 위와 같은 유출 내지 이용행위에 공모·가담하였다 하더라도 그 타인의 사무를 처리하는 자의 지위에 있다는 등의 사정이 없는 한 업무상배임죄의 공범 역시 성립할 수 없다.”

 

3.    실무적 시사점 

 

기술유출 분쟁에서는 이직한 직원 뿐만 아니라 그 직원을 채용한 경쟁사에 대한 제재를 목적으로 법적조치를 취하는 경우가 많습니다. 실무적으로 경쟁사에게 어떤 법적 책임을 물을 수 있는지가 매우 중요합니다.

 

통상 영업비밀침해죄의 공동불법행위책임, 공범 등으로 책임을 물을 수 있습니다. 또한 전직한 직원에게 업무상 배임죄 책임이 있는 경우에는 경쟁사에 대해서도 마찬가지로 공동불법행위, 공범의 책임을 지울 수 있습니다.

 

다만, 첨부한 판결 사안과 같이 시간적 간격이 있는 경우라면 업무상 배임죄가 성립하는지는 신중하게 판단해야 할 것입니다. 대법원 판결에서 회사의 업무상 배임의 공범 성립의 범위를 판시한 부분을 찬찬히 읽어 보시기 바랍니다.

 

첨부: 대법원 2017. 6. 29. 선 20173808 판결

  대법원 2017도3808 판결 .pdf

 

 

작성일시 : 2017.07.03 17:50
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

전직금지 또는 경업금지소송에서 자주 문제되는 쟁점입니다. 사용자와 근로자 사이에 전직금지 또는 경업금지 약정을 하였지만, 사용자가 근로자에게 전직금지에 대한 어떤 반대급부(대가)도 지급하지 않았던 경우에도 그 약정에 따라 전직금지 또는 경업금지 의무(채무)를 강제할 수 있는지 여부입니다. 실무적으로 단순하게 판단하기 어려운 쟁점입니다. 

 

이론적 논의와는 별개로 실제로 사용자가 퇴직 근로자에게 전직금지 대가를 지급하는 경우가 거의 없습니다. 현실적으로 대기업 고위임원에 대한 고문제도를 제외하고는 대가지급 제도는 전무하다 싶습니다.

 

최근 대리직급의 엔지니어가 경쟁사로 이직한 사건에서 서울고등법원 결정문에 판시한 내용을 참고할 수 있습니다. 결정문을 인용하면 다음과 같습니다.

 

퇴직 후 근로자의 경업이 중요한 영업비밀의 누설을 동반하는 등 사용자에게 현저하게 배신적인 경우에는 경업금지에 대한 대가조치가 없더라도 사용자를 구제하여야 할 경우가 생길 수 있지만(다만 현행법질서에서 대부분은 부정경쟁방지 및 영업비밀보호에 관한 법률에 정해진 금지청구로써 위와 같은 부정경쟁행위에 대처하고 비밀을 보호할 수 있다고 할 것이다),

 

경업금지의무는 근로자의 직업활동의 자유를 직접적으로 제약하는 강력한 의무이므로 근로자에게 일방적으로 그 의무를 부담시키는 방향으로 해석하는 것은 적절하지 않고, 퇴직 후에 근로자는 스스로 경험과 지식을 활용해서 자유롭게 경업을 영위하는 것이 헌법 제15(직업선택의 자유)의 취지이며, 이와 같은 기본적 자유를 제한하기 위해서는 원칙적으로 근로자가 그 제약에 따라 입는 손해를 전보하기에 충분한 정도의 반대급부(대가)가 필요하다고 할 것이다.”

 

정리하면, (1) 퇴직자에 대한 영업비밀침해금지청구를 인정할 정도로 근로자의 사용자에 대한 배신성이 현저한 경우라면 대가 지급과 무관하게 전직금지 의무를 인정할 수 있으나,

 

(2) 원칙적으로 전직금지 약정을 강제하려면 사용자의 근로자에게 대한 대가지급이 필요하기 때문에 특별한 사정이 없는 한 그와 같은 대가지금이 없다면 전직금지 약정만에 기초한 전직금지청구는 인정되지 않는다는 것입니다.

 

 

작성일시 : 2017.07.03 13:02
Trackback 0 : Comment 0

댓글을 달아 주세요